Primary Myelofibrosis - ClinicalTrials.gov

A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib

DIPSS -Intermediate or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis — Treated with Ruxolitinib This is a Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS -Intermediate or Branchesis elo a Mye or High Risk Primary Mye Effic otinib e or High Risk Mye o e Mye e Mye e Myetinib a Mye etelofibrosis elofibrosis —Myelo a Myeloblamye e Myelofibrosis, Post-Label Efficence and Safety Trial of DIPSSer Cycle 6 as the primary aim, a spleen volume reduction at the end of the year.

Source link: https://clinicaltrials.gov/ct2/show/NCT03755518

A Phase II Study of Decitabine in Myelofibrosis

Patients with myelofibrosis are affected by the decitabine's response rate. In myeloid metaplasia with myelofibrosis, a decitabine-based hemoglobin F levels and absolute numbers of circulating clusters of differentiation 34+ progenitor cells will be determined by the researcher to investigate the potential use of these markers as a surrogate for biologic activity of decitabine.

Source link: https://clinicaltrials.gov/ct2/show/NCT00095784

TGR-1202 + Ruxolitinib in Subjects With Myelofibrosis, MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea

Myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic doses of ruxolitinib are expected to attend maximal response at the highest tolerated dose of ruxolitinib, but not as discussed among investigators. Patients in Stage 2 of JAK Inhibitor nau00efve are expected to receive TGR-1202 at the recommended dose established in Cohort 1, as well as ruxolitinib. Patients in Stage 1 will be exposed to ruxolitinib at different doses, and dose levels in Stage 2 will rise to meet safety testing requirements.

Source link: https://clinicaltrials.gov/ct2/show/NCT02493530

A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis

Myelofibrosis is a bone marrow disease that affects blood-forming tissues in the body. When given alone, and in conjunction with ruxolitinib or navitoclax, adult participants with MF, the aim of this research is to see how safe and tolerable ABBV-744 is. Participants in Segment A will be given different doses and times of the oral ABBV-744 tablet to determine a safe dosing regimen. Participants in Segment B's oral ruxolitinib and ABBV-744 will be given as a "add-on" therapy. Participants of Segment C will be given ABBV-744 and oral navitoclax. Participants in Segment D will be sent ABBV-744 and ruxolitinib. Participants will be treated until disease progression is determined, unless the participants are unable to tolerate the study medications. Participants in this trial may have a higher healthcare burden than those who receive them.

Source link: https://clinicaltrials.gov/ct2/show/NCT04454658

Phase I Study of AVID200 in Patients With Myelofibrosis (Myeloproliferative Neoplasms Research Consortium [MPN-RC] 118)

The study team believes that blocking the TGF-u03b2 signaling pathway in MF will reduce the fibrogenic stimuli leading to myelofibrosis, prematurely stop myelofibrosis, concomitantly interrupt myelofibrosis and restore normal hematopoiesis. AVID200 is a fusion protein that contains TGF-u03b2 receptor ectodomains fused to a human Fc IgG domain. AVID200 is a powerful TGF-u03b2 trap with antibody-like properties that has pM potency against two of the three TGF-u03b2 ligands, TGFu03b21 and u03b23.

Source link: https://clinicaltrials.gov/ct2/show/NCT03895112

A Phase 2 Study of Canakinumab in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 122]

On day 1 of a 21-day cycle for a core study period of 8 cycles, eligible patients will receive Canakinumab as a subcutaneous injection. If the total number of patients exceeds the maximum sample size of 26, the therapy is considered acceptable if the number of responses in the efficacy endpoint exceeds three, and the number of toxicities is less than 7.

Source link: https://clinicaltrials.gov/ct2/show/NCT05467800

Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelofibrosis and Chronic Myelomonocytic Leukemia

The leading cause of treatment failure after hematopoietic cell transplantation is relapsed disease. On days 1 through three of cycles, and then on days 1 and 2 of subsequent cycles, for up to nine cycles or until disease progression or if you have a bad side effect, the tag will be administered by IV over the next three days. Participants will have a bone marrow biopsy and then a questionnaire about their quality of life after about four cycles of chemotherapy and then about one year after HCT, and then again about a year after HCT.

Source link: https://clinicaltrials.gov/ct2/show/NCT05233618

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions